DHIVY is now available 
for Parkinson’s disease

Introducing the first and only carbidopa/levodopa
tablet that was designed to be divided1,2

Fingers snapping a DHIVY tablet

DHIVY is an immediate-release tablet with 4 snappable 
segments—giving you a range of dosing amounts in each tablet.

1 whole DHIVY tablet

1 whole tablet (25/100 mg)

3 quarters of a DHIVY tablet

3/4 tablet (18.75/75 mg)

Half a DHIVY tablet

1/2 tablet (12.5/50 mg)

One quarter of a DHIVY tablet

1/4 tablet (6.25/25 mg)

DHIVY offers a new way to personalize every dose to suit your unique day

Side view of enlarged DHIVY tablet

Ask your doctor if DHIVY 
is right for you.

Images do not represent the actual size of the tablet.

Find co-pay support

If you’re eligible, you could pay as little as $50 per 30-day fill of DHIVY.

Stay up to date on DHIVY

More information is on the way—be the first to know when updates are available.

All fields are required.

Thanks for signing up!

You’ll receive more
information about DHIVY.


DHIVY is a combination of carbidopa and levodopa indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.


Do not take DHIVY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within 2 weeks of each other can result in high blood pressure. Do not take DHIVY if you have hypersensitivity to any ingredient of DHIVY.

Taking DHIVY may result in falling asleep while engaged in normal activities, even without warning and as late as one year or later after starting DHIVY. Do not drive or operate machinery until you know how DHIVY affects you.

Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats; if you experience hallucinations or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking); if you have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges; if dyskinesia or abnormal involuntary movements appear or get worse during treatment with DHIVY; if you have ever had a peptic ulcer or glaucoma; if you have any abnormal lab results; or if you experience depression or suicidal thoughts.

Notify your healthcare provider if you become pregnant or intend to become pregnant during DHIVY therapy or if you intend to breastfeed or are breastfeeding an infant.

Talk to your healthcare provider before you lower the dose or stop taking DHIVY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.

Take DHIVY as instructed. You may take DHIVY with or without food. If you have difficulty swallowing the tablet due to its size, you may break the tablet along the score lines.

The most common adverse reactions reported with carbidopa/levodopa tablets have included abnormal involuntary movements and nausea.

Please see full Prescribing Information.

References: 1. DHIVY. Package insert. Avion Pharmaceuticals, LLC; 2021. 2. SINEMET. Package insert. Merck Sharp & Dohme Corp.; 2020.